Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Sunday, Oct 08, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x